Chromatin Structure and DNA Repair Shaped a Multiple Myeloma Chemotherapy Study Now Retracted

A landmark study that promised to explain why some patients with multiple myeloma respond to chemotherapy while others do not has been formally retracted, closing a twelve-year chapter in cancer research. The retraction note, published in the British Journal of Cancer on 15 October 2026, withdraws the 2014 paper ‘Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma,’ a work that had linked the physical organization of DNA inside cancer cells to the success or failure of standard myeloma treatments.

The original research had proposed an elegant biological framework. Multiple myeloma is a cancer of plasma cells, the antibody-producing cells of the immune system, and its treatment typically involves DNA-damaging agents such as alkylating drugs. The authors argued that the way DNA is packaged into chromatin, the tightly coiled complex of DNA and proteins inside the nucleus, determines how efficiently a myeloma cell can repair the damage inflicted by chemotherapy. Cells with open, transcriptionally active chromatin were suggested to repair DNA differently from cells with condensed, silent chromatin, and this difference was proposed to influence clinical outcomes.

That hypothesis was scientifically compelling because it connected three levels of biology into a single predictive model. At the molecular level, chromatin structure controls access of repair enzymes to damaged DNA. At the cellular level, repair efficiency determines whether a cancer cell survives treatment. At the clinical level, survival and relapse patterns reflect those cellular decisions aggregated across millions of tumor cells. A validated version of this model could have guided oncologists in selecting therapies based on the epigenetic state of a patient’s myeloma cells, potentially transforming treatment planning for a disease that remains incurable despite decades of therapeutic advances.

The retraction, however, was triggered not by a failure of the underlying biology but by irregularities in the published figures. The Editor-in-Chief of the British Journal of Cancer identified several image problems that undermined confidence in the paper’s data. Figure 1A and Figure 1B appeared to partially overlap, suggesting that panels intended to show different experimental conditions may have contained duplicated content. Multiple partial overlaps were also detected among Figures 1E through 1K, a pattern that image-integrity specialists interpret as evidence that the same underlying data may have been reused across panels presenting distinct results.

More troubling still were the cross-publication overlaps. Figure 1F through 1H in the retracted article appeared to partially overlap with Figure 3F through 3H in a separate 2016 paper published in the journal Blood, which examined DNA repair in myeloma plasma cells and the effect of the nonhomologous end-joining inhibitor SCR7. When identical or nearly identical images appear in different papers describing different experiments, the concern extends beyond a single study and raises questions about the reliability of an entire body of work. Additional overlaps were found within Figure 3C of the retracted article itself, where panels labeled for different p53-related experimental conditions, including designations referred to as S15-p53 with high variability, normal response, and resistant categories, appeared to share partially duplicated content.

The investigation faced a fundamental obstacle that will resonate with anyone following the reproducibility crisis in science. Because of the age of the article, the original data were no longer available. Without the underlying raw files, the authors had no way to demonstrate that the overlapping images resulted from innocent formatting errors rather than from manipulation or data reuse. The authors could not provide a satisfactory response to the several concerns raised, and the Editor-in-Chief therefore concluded that confidence in the reliability of the reported data could no longer be maintained.

The authors’ responses during the investigation varied in a way that itself carries scientific weight. S. A. Kyrtopoulos, M. A. Dimopoulos, and V. L. Souliotis did not respond to correspondence from the publisher about the editorial expression of concern. The publisher was unable to contact M. Gkotzamanidou, P. P. Sfikakis, and C. Bamia at all. This pattern of non-response and unreachable authors has become a familiar feature of retraction cases, and it highlights a structural weakness in the self-correction machinery of science: journals can withdraw a paper, but they cannot compel authors to engage with the process or explain what happened to their data.

The retraction also implicates a linked study, since the 2016 Blood paper on DNA repair in myeloma plasma cells and the SCR7 inhibitor is cited in the retraction note as the source of one set of overlapping figures. That paper had reported that DNA repair capacity in myeloma plasma cells correlates with clinical outcome and that pharmacological inhibition of nonhomologous end-joining, one of the two major pathways cells use to repair DNA double-strand breaks, could affect treatment results. SCR7 works by interfering with DNA ligase IV, an enzyme essential for sealing the breaks created by the nonhomologous end-joining machinery, thereby pushing cells toward less faithful repair routes and theoretically increasing chemotherapy sensitivity. Whether that paper will face its own editorial action remains to be seen, but the shared image irregularities mean its findings must now be interpreted with caution.

For the myeloma research community, the loss of this paper removes a piece of a larger puzzle rather than demolishing the puzzle itself. The idea that chromatin architecture and transcriptional state modulate DNA repair outcomes remains an active and well-supported area of investigation in many cancer types. Genome-wide mapping technologies, single-cell epigenetic profiling, and CRISPR-based perturbation experiments have since provided far more rigorous tools for testing how chromatin accessibility shapes repair pathway choice at DNA breaks. The retracted study’s central question, why identical chemotherapy regimens produce wildly different outcomes in different patients, remains one of the most important unsolved problems in hematologic oncology.

The case also serves as a vivid reminder of how modern science polices itself. Automated image-forensics tools and diligent readers now routinely detect duplicated panels that escaped peer review years earlier, and journals increasingly act on concerns even when the original data have vanished. The retraction note ends without vindication or explanation, only the stark editorial conclusion that the Editor-in-Chief no longer has confidence in the reliability of the data reported. For patients and researchers alike, the episode underscores that scientific progress depends not only on bold hypotheses about chromatin, transcription, and DNA repair, but on the integrity of every image, every dataset, and every claim that carries those hypotheses into the medical literature.

Subject of Research: retraction

Article Title: Retraction Note: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma

Article References: Retraction Note: Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma. (n.d.). https://doi.org/10.1038/s41416-026-03646-0

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03646-0

Keywords: retraction, multiple myeloma, DNA repair, chromatin, research integrity, British Journal of Cancer, chemotherapy, Note, structure, transcriptional, activity, repair